Contineum Therapeutics (CTNM) to Release Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $3.81 on Wednesday. The company has a market cap of $98.57 million and a P/E ratio of -0.78. The stock’s 50-day moving average is $5.50 and its 200-day moving average is $10.20. Contineum Therapeutics has a 52-week low of $3.64 and a 52-week high of $22.00.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CTNM shares. Morgan Stanley reissued an “overweight” rating and issued a $25.00 price objective on shares of Contineum Therapeutics in a research report on Friday, March 7th. Jones Trading began coverage on shares of Contineum Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $23.00 price target for the company. Finally, Robert W. Baird decreased their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $23.75.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).